Get started
Work

CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC

Year: 2019
Type: article
DOI: 10.1093/annonc/mdz437.056
Authors: B.C. Cho, G.-C. Chang, Y.-C. Kim, S. Geater, S. Saeteng, C.-T. Yang, Y. Goto, S. Lu, A. Ardizzoni, F. Barlesi, P. De Marchi, L. Paz-Ares, D.R. Spigel, M. Thomas, E.B. Garon, M. Leung, J. Baum, Z. Zewen, B. Mookerjee, J.C.-H. Yang
Institutions: Yonsei University, Yonsei University Health System, Taichung Veterans General Hospital, Chonnam National University Hwasun Hospital, Songklanagarind Hospital, Chiang Mai University, Chang Gung Memorial Hospital, Taoyuan Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, National Cancer Center Hospital, Shanghai Chest Hospital, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Aix-Marseille Université, Hospital de Câncer de Barretos, Hospital Universitario 12 De Octubre, Heidelberg University, University Hospital Heidelberg, German Center for Lung Research, University of California, Los Angeles, Novartis (United States), National Taiwan University Hospital
Language: English
Field: Medicine
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Celgene, Array BioPharma, Merck KGaA, Yuhan, Korea Health Industry Development Institute, Ono Pharmaceutical, Genentech, EMD Serono, Loxo Oncology
OpenAlex ID: W2990766679
FWCI:
Cites:
Cited by:
Related to: 10